Topotecan for the treatment of recurrent and stage IVB cervical cancer

  • Technology appraisal guidance
  • TA183
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 NICE proposes that the guidance on this technology is considered for review by the Guidance Executive in September 2012. NICE welcomes comment on this proposed date. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
October 2009

  • National Institute for Health and Care Excellence (NICE)